Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | BLK | P51451 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | STK3 | Q13188 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL477913 | 0.79 | CDK2 (0.56) | GSK3BPLK4AURKACHEK2LCK | |
| SCHEMBL12367151 | 0.78 | GSK3B (0.51) | GSK3BPLK4AURKACHEK2LCK | |
| SCHEMBL12367150 | 0.71 | CDK2 (0.43) | GSK3BPLK4AURKACHEK2LCK | |
| SCHEMBL12367153 | 0.71 | CDK2 (0.43) | GSK3BPLK4AURKACHEK2LCK | |
| SCHEMBL12367147 | 0.71 | PLK4 (0.37) | GSK3BPLK4AURKACHEK2LCK | |
| SCHEMBL1367080 | 0.69 | CYP1A2 (0.55) | GSK3BPLK4AURKACHEK2LCK | |
| SCHEMBL6015921 | 0.69 | MEN1 (0.62) | CYP1A2SMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL6015927 | 0.69 | MEN1 (0.62) | CYP1A2SMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL12367146 | 0.69 | PLK4 (0.38) | GSK3BPLK4AURKACHEK2LCK | |
| SCHEMBL12690199 | 0.67 | STK17B (0.58) | GSK3BSMN1; SMN2MAPTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994160-B2 | Pyridazine compounds as glycogen synthase kinase 3 inhibitors | ABBOTT GMBH & CO. KG (DE) | 2011-08-09 | — | — | US | disclosed |
| US-20090325937-A1 | Pyridazine Compounds as Glycogen Synthase Kinase 3 Inhibitors | ABBOTT GMBH & CO. KG (DE) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325937-A1 | Pyridazine Compounds as Glycogen Synthase Kinase 3 Inhibitors | GSK3B, GSK3A, GYS2 | GSK3B 1/4885PLK4 39/4885AURKA 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.